<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591262</url>
  </required_header>
  <id_info>
    <org_study_id>C2501006</org_study_id>
    <nct_id>NCT04591262</nct_id>
  </id_info>
  <brief_title>A Study To Asses Mass Balance And Absolute Bioavailability Of 14C PF-06826647 In Healthy Male Participants</brief_title>
  <official_title>A PHASE 1, OPEN LABEL, 2-PERIOD, FIXED SEQUENCE, STUDY TO ASSESS THE MASS BALANCE, ABSOLUTE BIOAVAILABILITY OF 14C PF 06826647 IN HEALTHY MALE PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the metabolism and excretion following a single oral&#xD;
      administration of 14C-PF-06826647-LR (14C labelled PF-06826647 with lower radioactivity per&#xD;
      mass unit) in fed conditions. This information will enable assessment of clearance mechanisms&#xD;
      of PF-06826647 as well as identify metabolites. In addition, this study will determine&#xD;
      absolute bioavailability of PF-06826647 and understand intravenous (IV) pharmacokinetic (PK).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Actual">January 28, 2021</completion_date>
  <primary_completion_date type="Actual">January 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total radioactivity in urine and feces together expressed as percent of total oral radioactive dose</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Test Values of Potential Clinical Importance</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal ECG</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Criteria for ECG abnormalities: maximum PR interval &gt;=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) &gt;=25 percent (%) for baseline value of &gt;200 msec and Pctchg&gt;=50% for baseline value of &lt;=200 msec for PR interval, maximum QRS interval &gt;=140 msec and a maximum IFB: Pctchg&gt;=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to &lt;480 msec, 480 msec to &lt;500 msec or &gt;=500 msec and a maximum change of &lt;=30change&lt;60 or &gt;=60 msec from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Following parameters were analyzed for examination of vital signs: systolic and diastolic blood pressure, respiratory rate, radial pulse and body temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of dose normalized AUCinf of PF-06826647 and 14C-PF-06826647</measure>
    <time_frame>0 hours to 96 hours</time_frame>
    <description>The ratio of dose normalized AUCinf of PF-06826647 (LCMS) and 14C-PF-06826647 (AMS). AUCinf= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time . It is obtained from AUC (0 - t) plus AUC (t - âˆž).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-06826647 600 mg PO&gt;PF-06826647 600 mg PO+100 ug IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06826647 600 mg single dose in Period 1 followed by PF-06826647 600 mg PO and IV infusion of 100 ug of PF-06826647 in Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-PF-06826647-LR 600 mg PO</intervention_name>
    <description>14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep</description>
    <arm_group_label>PF-06826647 600 mg PO&gt;PF-06826647 600 mg PO+100 ug IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06826647 600 mg PO</intervention_name>
    <description>Unlabeled PF-06826647 600 mg</description>
    <arm_group_label>PF-06826647 600 mg PO&gt;PF-06826647 600 mg PO+100 ug IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-PF-06826647 100 ug IV</intervention_name>
    <description>14C-PF-06826647 100 ug IV</description>
    <arm_group_label>PF-06826647 600 mg PO&gt;PF-06826647 600 mg PO+100 ug IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Male participants must be 18 to 55 years of age, inclusive.&#xD;
&#xD;
          -  Male participants who are overtly healthy as determined by medical evaluation&#xD;
             including medical history, physical examination, including BP and pulse rate&#xD;
             measurement, laboratory tests, and 12 lead ECG.&#xD;
&#xD;
          -  Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
          -  BMI of 17.5 to 30 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or&#xD;
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies at the time of dosing).&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  History of irregular bowel movements including irritable bowel syndrome or frequent&#xD;
             episodes of diarrhea or constipation defined by less than 1 bowel movement on average&#xD;
             per 2 days or lactose intolerance.&#xD;
&#xD;
          -  Participants who currently use or have formerly used (within 6 months of dosing)&#xD;
             tobacco or nicotine containing products.&#xD;
&#xD;
          -  Total 14C radioactivity measured in plasma exceeding 11 mBq/mL.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C2501006</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADME, Mass Balance, Absolute Bioavailability, AMS</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

